Safety, Tolerability, and Pharmacokinetics of Topical Calcitriol Formulation for Treatment of Chemotherapy-Induced Alopecia in Patients Receiving Taxane-Based Regimen: Final Results

    May 2019 in “ Journal of clinical oncology ”
    Mario E. Lacouture, Rangaprasad Sarangarajan, Joaquín J. Jiménez … Shari Goldfarb
    Studysummary This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ascopubs.org →
    Discuss this study in the Community →